Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98150 | 0.93 | MAPT (0.40) | HDAC1PIK3CDPIK3CAMTORLMNA | |
| SCHEMBL1620566 | 0.87 | PIK3CA (0.42) | HDAC1PIK3CDPIK3CAPIK3CBLMNA | |
| SCHEMBL1620548 | 0.86 | HDAC1 (0.43) | HDAC1PIK3CDPIK3CAPIK3CBLMNA | |
| SCHEMBL16556630 | 0.82 | HDAC1 (0.43) | HDAC1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL97899 | 0.81 | MAPT (0.45) | HDAC1PIK3CALMNAMEN1KMT2A | |
| SCHEMBL99288 | 0.80 | GAA (0.42) | HDAC1PIK3CDPIK3CAPIK3CBLMNA | |
| SCHEMBL98839 | 0.80 | MAPT (0.43) | HDAC1PIK3CDPIK3CALMNANPSR1 | |
| SCHEMBL1620501 | 0.80 | MAPT (0.44) | HDAC1PIK3CALMNAMEN1KMT2A | |
| SCHEMBL97115 | 0.80 | TP53 (0.44) | HDAC1PIK3CALMNANPSR1MEN1 | |
| Hydrochloric Acid SCHEMBL99386 | 0.79 | TP53 (0.43) | HDAC1PIK3CALMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132130-B2 | Purine derivative and antitumor agent using same | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088765-A1 | PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME | PNP, TYMP, DPYD | HDAC1 3179/4885PIK3CD 2513/4885PIK3CA 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.